DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00233649
First received: October 5, 2005
Last updated: November 18, 2010
Last verified: November 2010
  Purpose

The purpose of this study is to determine in DM II patients the efficacy of Crestor in obtaining the new European LDL cholesterol guidelines.


Condition Phase
Diabetes Mellitus Type 2
Crestor, Rosuvastatin
LDL Cholesterol
Observational
Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Estimated Enrollment: 2500
Study Start Date: May 2004
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Diabetes Mellitus Type 2

Criteria

Inclusion Criteria:

  • Diabetes Mellitus Type 2, LDL-C > 2,5 mmol/l, no cholesterol lowering medication used last 3 months, starts with Crestor 10 mg, permission to use patient data by AZ
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00233649

  Show 222 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Astra Zeneca AstraZeneca
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00233649     History of Changes
Other Study ID Numbers: NL401017
Study First Received: October 5, 2005
Last Updated: November 18, 2010
Health Authority: European Union: European Medicines Agency

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on August 26, 2014